Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare law that ...

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

The U.S. Food and Drug Administration (FDA) has approved several label updates for CAR-T cell therapies marketed by Bristol ...

Microsoft (NASDAQ:MSFT) stock fell 0.5% in pre-market trading on Friday following a report from The Information that the company’s next-generation AI chip is facing a delay of at least six months.

Boeing is entering a new phase of recovery that could support a market reassessment of its stock, according to analysts at Redburn.

The U.S. Supreme Court could make a decision Friday that would rattle Gilead Sciences' newest HIV prevention drug.

It's a case of so far, so good for BlueRock Therapeutics' first clinical trial of Parkinson's disease therapy bemdaneprocel, ... Kymera signs $750m cancer deal with Gilead as Sanofi opts in.